Loading…
← CockpitCompetitor Analysis › 688759.SS BeBetter Med, Inc. Class AOpen in the cockpit ↗

BeBetter Med, Inc. Class A688759.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Guangzhou clinical-stage biotech developing small-molecule cancer drugs, largely pre-revenue.

≈ A small, China-based oncology biotechMomentum laggard 2
Mkt cap
$960M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$15.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 17.9%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥14.70
1D-2.3%
1W-10.9%
1M-19.4%
3M-48.0%
6M-57.8%
YTD-49.4%
1Y-53.6%
ATR %6.5%
52w lowhigh74.4% off high

What BeBetter Med does

Guangzhou clinical-stage biotech developing small-molecule cancer drugs, largely pre-revenue.

In one line: A small, China-based oncology biotech.

Products and services

  • Oncology drug candidates

Where it sits in the supply chain

  • Pharmaceuticals
  • Clinical-stage biotech
  • Oncology small molecules

What could go right

  • Positive trial data
  • Licensing deals with global pharma

What could go wrong

  • Trial failure risk
  • Ongoing cash burn

Moat: none (IP / patents). Value depends on unproven clinical pipeline rather than an approved product.

Headquarters: Guangzhou, China · Employees: 160

Named competitors

BeBetter Med at a glance

Size BeBetter Med (688759.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $960M, the 2229th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.70 on 18 Nov 2026.

Performance Over six months the shares fell 57.8%, against -12.1% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 87688759.SS 42
Six months, rebased to 100: BeBetter Med against the median of its 20 peers (local-currency closes).

BeBetter Med financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥0CN¥0CN¥0CN¥0CN¥0
Revenue growth—————
Gross profitCN¥0-CN¥13.7M-CN¥13.4M-CN¥10.5M-CN¥4.94M
EBITDAn/a-CN¥164M-CN¥150M-CN¥184M-CN¥221M
Net income-CN¥291M-CN¥154M-CN¥56.0M-CN¥173M-CN¥188M
Free cash flow-CN¥261M-CN¥109M-CN¥107M-CN¥145M-CN¥170M
Capital expenditureCN¥61.7MCN¥10.7MCN¥18.9MCN¥18.3MCN¥42.3M
Total debtCN¥3.12MCN¥4.39MCN¥5.84MCN¥6.08MCN¥8.41M

Quarterly statements and history in the cockpit →

BeBetter Med competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%30029420054565STAR603538PGHLSPTX002437600422600129688382AARTIPHARM600252600557688177039200688710605116688091688759.SS6-month return →1-month return →
Up and to the right = strong over both horizons. BeBetter Med is the large dot.

BeBetter Med competitors and peer comparison

Head to head with its named competitors (688759.SS vs 600276.SS vs 688235.SS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
BeBetter Med 688759.SS$960M-58%n/an/an/an/a
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%8.0×13.4%
BeOne Medicines 688235.SS$45.5B+9%+25%18%6.3×19.1%

How BeBetter Med compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

BeBetter Med against its 20 peers (data as of 18 Nov 2026)
Measure688759.SSPeer medianRank in peer set
1-month return-19.4%-8.3%2nd lowest of 21
6-month return-57.8%-12.1%lowest of 21
Distance from 52-week high-74.4%-41.9%lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%2.5×n/an/a
SSY 2005.HKHong Kong$948M+8%-4%12%2.2×2.3%-0.5%
Nxera Pharma 4565.TJapan$974M+46%+24%14%5.4×17.7%+27.3%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%2.0×17.6%+7.8%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%3.8×11.6%+4.9%
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%6.3×5.6%+9.3%
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%2.8×7.7%-6.9%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%1.8×n/an/a
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%1.3×n/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%75.0×6.5%-60.6%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%4.7×n/an/a
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%4.5×10.3%-13.7%
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%1.4×2.3%+1.8%
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%6.5×n/an/a
Oscotec 039200.KSSouth Korea$923M-32%+510%59%7.5×-10.2%+18.1%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%5.2×12.7%+19.4%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%5.2×9.1%+13.4%
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%4.2×-2.0%+18.7%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%19.3×n/an/a

Questions

Who are BeBetter Med's main competitors?
Named competitors: Hengrui Medicine (600276.SS), BeiGene (688235.SS). The cockpit's measured peer set (industry) also includes China Resources Boya Bio-pharmaceutical (300294.SZ), SSY (2005.HK), Nxera Pharma (4565.T), Strides Pharma Science (STAR.NS), Ningbo Menovo Pharmaceutical (603538.SS), Procter & Gamble Health (PGHL.NS).
How has BeBetter Med stock performed?
Over six months to 18 Nov 2026 the shares returned -57.8% against -12.1% for the median peer; over one year -53.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.